Abstract:Objective To evaluate the risk factors of acute-phase reaction (APR)following the first-dose administration of zoledronic acid in osteoporotic patients. Methods The documents of the observational studies about risk factors of APR following the first-dose administration of zoledronic acid in osteoporotic patients were searched from correlative data base until July,2017. The quality of the literature enrolled into the Meta-analysis was evaluated by Newcastle-Ottawa Scale (NOS),and then Meta-analysis was conducted using RevMan 5. 3 software. The effective measurements were expressed as adds ratio (OR) or difference in means (MD)and 95％ confidence interval (CI). Results A total of 17 studies involving 1981 patients with osteoporotic and having the first-dose administration of zoledronic acid were enrolled into the Meta-analysis. Nine hundred and seventy-nine patients had APR (APR + group)and 1002 patients without APR (APR - group). The scores of NOS in 17 articles were all greater than or equal to 6. The results of Meta-analysis showed that the patients in the APR(+)group were significantly younger then those in the APR(-)group (MD = - 3. 27,95％ CI:- 4. 54- - 2. 01,P < 0. 00001). The incidence rate of APR in the patients who had the history of administration of nitrogenous bisphosphonates (NBP)were lower than those without history of administration of NBP,and the difference was statistically significant (OR =0. 27,95％ CI:0. 17-0. 41,P < 0. 00001). The incidence rate of APR in the patients having the history of fracture were higher than those without history of fracture,and the difference was statistically significant (OR =2. 31,95％ CI:1. 29-4. 13,P = 0. 005). The incidence rate of APR in the patients who had analgesic-antipyretic preventability treatment were lower than those who had no analgesic-antipyretic preventability treatment,and the difference was statistically significant (OR = 0. 14,95％ CI:0. 05-0. 37,P < 0. 0001). There were no statistical correlation between the patients′ body mass index,creatinine clearance,prior calcium usage,prior calcitriol usage,sex and APR. Conclusion Low age and the history of fracture are risk factors of APR,while the histories of administration of NBP and analgesic-antipyretic preventability are the protective factors of decreasing APR.

Change in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study

The Change in Body Temperature, Not Acute-Phase Reaction, Predicts anit-Osteoporosis Efficacy after the First Administration of Zoledronic Acid in a self-control study

The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients

Multicenter Study on Observation of Acute-phase Responses after Infusion of Zoledronic Acid 5 Mg in Chinese Women with Postmenopausal Osteoporosis

Risk factors of acute-phase reaction following the first-dose administration of zoledronic acid in osteoporotic patients:a Meta-analysis

Risk factors and measures of acute-phase reactions caused by zoledronic acid injection for treating osteoporosis

Observation of the efficacy and safety of zoledronic and in postmenopausal osteoporosis

Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial

Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion

Zoledronic Acid Increases Bone Mineral Density and Improves Health-Related Quality of Life over Two Years of Treatment in Chinese Women with Postmenopausal Osteoporosis.

Identifying therapeutic biomarkers of zoledronic acid by metabolomics

Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study

Reducing Re-fractures Post Percutaneous Kyphoplasty: The Impact of Zoledronic Acid with Calcium and Vitamin D3 in Osteoporotic Patients

Effect of 5 Mg Zoledronic Acid on Bone Mineral Density in Women with Postmenopausal Osteoporosis

Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials

[Phase III Clinical Study of Zoledronic Acid in the Treatment of Pain Induced by Bone Metastasis from Solid Tumor or Multiple Myeloma].

Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance

The effect of Zoledronic acid on pain and balance in women with postmenopausal osteoporosis

5 Mg Zoledronic Acid for Treatment of Postmenopausal Women with Osteoporosis and Osteoporotic Fracture

Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial